Description

Ac-Lys-Val-Cit-PABC-MMAE is a agent-linker conjugate for ADC. Ac-Lys-Val-Cit-PABC-MMAE contains the ADC linker (peptide Ac-Lys-Val-Cit-PABC) and a potent tubulin polymerization inhibitor MMAE (HY-15162)[1].–20°C (Powder, protect from light)-Applications-Cancer-programmed cell death-Formula-C66H108N12O14-Citation–References-[1]Kleniman, et al. Engineered polypeptide conjugates. WO2015015448A2. -CASNumber-1650569-89-3-MolecularWeight-1293.64-Compound Purity-99.99-SMILES-O[C@@H](C1=CC=CC=C1)[C@@H](C)NC([C@H](C)[C@H]([C@@]2([H])N(CCC2)C(C[C@@H](OC)[C@H]([C@@H](C)CC)N(C)C([C@H](C(C)C)NC([C@H](C(C)C)N(C)C(OCC3=CC=C(C=C3)NC([C@H](CCCNC(N)=O)NC([C@H](C(C)C)NC([C@@H](NC(C)=O)CCCCN)=O)=O)=O)=O)=O)=O)=O)OC)=O-Research_Area-Cancer-Solubility-DMSO : ≥ 200 mg/mL-Target-Drug-Linker Conjugates for ADC-Isoform-Auristatin-Pathway-Antibody-drug Conjugate/ADC Related-MCE Product type-ADC Related